Loading..

AC Immune SA (ACIU) Report Analysis

Corporate Events

Positive

AC Immune SA Provides Update on Alzheimer's Pre...

2022-06-16 05:00:00

AC Immune SA announced results from the Alzheimer’s Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease (ADAD) Colombia Trial. ...

Neutral

AC Immune SA Presents at 2022 Jefferies Global ...

2022-05-31 11:30:00

AC Immune SA Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 08:00 AM. Venue: Marriott Marquis, New York City, New York, ...

Neutral

AC Immune SA, Annual General Meeting, Jun 24, 2022

2022-05-25 20:30:00

AC Immune SA, Annual General Meeting, Jun 24, 2022, at 14:30 Central European Standard Time. Agenda: To consider 2021 IFRS Consolidated Financ...

Neutral

AC Immune SA has closed its Shelf Registration ...

2022-05-19 00:00:00

AC Immune SA has closed its Shelf Registration dated August 24, 2018 in the amount of $57.7312 million. Security Name: Common Shares Secur...

Positive

AC Immune SA's Anti-Abeta Vaccine Results from ...

2022-05-09 15:00:00

AC Immune SA announced the publication in JAMA Neurology1 of data showing that AC Immune’s ACI-24 anti-Abeta vaccine was found to be safe and ...

Neutral

AC Immune SA Presents at B. Riley Securities's ...

2022-04-27 11:55:00

AC Immune SA Presents at B. Riley Securities's 2022 Virtual Neurology & Ophthalmology Conference, Apr-28-2022 11:30 AM. Speakers: Andrea Pfeif...

Negative

AC Immune SA Announces Executive Changes

2022-04-08 11:36:00

AC Immune SA announced senior management changes. Howard Donovan will join the Company as Chief HR Officer and be appointed to the Executive C...

Negative

AC Immune SA Announces Senior Management Changes

2022-04-08 11:36:00

AC Immune SA announced senior management changes. Joerg Hornstein, Chief Financial Officer, will leave in the second half to pursue a new oppo...

Neutral

B. Riley Securities, Inc., B. Riley Securities'...

2022-03-31 16:27:00

B. Riley Securities, Inc., B. Riley Securities's 2022 Virtual Neurology & Ophthalmology Conference, Apr 27, 2022 through Apr 28, 2022.

Neutral

AC Immune SA - Special Call

2022-03-29 00:00:00

Key Opinion Leader Webinar

Neutral

Jefferies LLC, 2022 Jefferies Global Healthcare...

2022-02-14 21:00:00

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New Yor...

Positive

AC Immune ACI-24 Data in Brain Communications S...

2022-02-04 12:30:00

AC Immune SA announced that preclinical data on the optimized formulation of its wholly-owned amyloid-beta (Abeta) vaccine program, ACI-24, we...

Neutral

AC Immune SA Presents at Inflammasome Therapeut...

2021-11-12 18:04:00

AC Immune SA Presents at Inflammasome Therapeutics Summit 2021, Nov-17-2021 12:00 PM. Speakers: Marie Kosco-Vilbois, Chief Scientific Officer.

Positive

AC Immune SA Presents New Interim Phase 1b/2a D...

2021-11-12 13:21:00

AC Immune SA presented new interim Phase 1b/2a data on ACI-35.030, a first-in-class anti-phosphorylated-Tau (pTau) vaccine candidate being dev...

Positive

AC Immune Announces Late-Breaker Presentation b...

2021-11-10 16:20:00

AC Immune SA announced that Genentech, a member of the Roche Group, presented the full topline data from Lauriet, a placebo-controlled Phase 2...

Neutral

SVB Leerink LLC, 11th SVB Leerink Annual Global...

2021-10-29 14:57:00

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022. Venue: New York, New York, Unit...

Negative

AC Immune SA Announces Board Changes

2021-10-29 10:00:00

AC Immune SA announced that the Company held an extraordinary general meeting (EGM) and elected Monica Shaw, M.D., and Prof. Monika Bütler, Dr...

Neutral

AC Immune SA Presents at 12th Annual Jefferies ...

2021-10-25 11:00:00

AC Immune SA Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-16-2021 through Nov-19-2021. Venue: London, United Kingdom. P...

Positive

AC Immune SA (NasdaqGM:ACIU) completed the acqu...

2021-10-13 00:00:00

AC Immune SA (NasdaqGM:ACIU) agreed to acquire Assets and Intellectual Property Related to Anti-Alpha-Synuclein Programs of AFFiRiS AG for $58...

Neutral

AC Immune SA, Special/Extraordinary Shareholder...

2021-10-07 11:27:00

AC Immune SA, Special/Extraordinary Shareholders Meeting, Oct 29, 2021, at 11:00 Central European Standard Time.

Neutral

AC Immune SA Proposes Amendments of the Article...

2021-10-07 11:27:00

AC Immune SA proposing to the Shareholders in its EGM held on October 29, 2021 to accept certain changes to the Company's Articles of Associat...

Neutral

Hanson Wade Limited, Inflammasome Therapeutics ...

2021-10-04 11:08:00

Hanson Wade Limited, Inflammasome Therapeutics Summit 2021, Nov 16, 2021 through Nov 18, 2021.

Neutral

AC Immune SA Presents at Morgan Stanley 19th An...

2021-09-02 11:00:00

AC Immune SA Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-10-2021 . Venue: New Windsor, United States.

Neutral

AC Immune SA Presents at H.C. Wainwright 23rd A...

2021-09-02 11:00:00

AC Immune SA Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-12-2021 through Sep-16-2021. Venue: Lotte New York Pala...

Neutral

AC Immune SA Presents at Citi’s 16th Annual Bio...

2021-09-01 19:46:00

AC Immune SA Presents at Citi’s 16th Annual BioPharma Virtual Conference, Sep-08-2021 . Venue: New York, United States.

Positive

AC Immune SA Announces First Positive Cognitive...

2021-08-31 11:30:00

AC Immune SA announced that Genentech, a member of the Roche Group, has informed the Company that Lauriet, a placebo-controlled Phase 2 study ...

Neutral

AC Immune SA Presents at Alzheimer's Associatio...

2021-07-29 11:30:00

AC Immune SA Presents at Alzheimer's Association International Conference, Jul-29-2021 10:00 AM. Venue: Denver, Colorado, United States.

Positive

AC Immune SA Presents Full Phase 1B Results on ...

2021-07-29 11:30:00

AC Immune SA announced that it outlined two presentations being delivered at the Alzheimer’s Association International Conference (AAIC) 2021,...

Positive

AC Immune SA - M&A Call

2021-07-27 11:30:00

To discuss on Strategic Acquisition of Parkinson’s Disease Vaccine Candidate and Equity Investment Led by Athos Service GmbH

Positive

AC Immune SA announced that it expects to recei...

2021-07-27 00:00:00

AC Immune SA entered into convertible note agreements to issue 2 unsecured subordinated convertible note at the price of $12.5 million per not...

Positive

AC Immune SA (NasdaqGM:ACIU) agreed to acquire ...

2021-07-27 00:00:00

AC Immune SA (NasdaqGM:ACIU) agreed to acquire Assets and Intellectual Property Related to Anti-Alpha-Synuclein Programs of AFFiRiS AG for $58...

Neutral

Alzheimer's Association, Alzheimer's Associatio...

2021-07-02 00:00:00

Alzheimer's Association, Alzheimer's Association International Conference, Jul 26, 2021 through Jul 30, 2021. Venue: Denver, Colorado, United States.

Positive

AC Immune SA Provides Update on Alzheimer's Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease

2022-06-16 05:00:00

AC Immune SA announced results from the Alzheimer’s Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease (ADAD) Colombia Trial. The study evaluated the potential of crenezumab, an investigational medicine, to slow or prevent Alzheimer’s disease in cognitively unimpaired people who carry a specific genetic mutation which causes early-onset Alzheimer’s disease. Numerical differences favouring crenezumab over placebo were observed across the co-primary, multiple secondary and exploratory endpoints, though none were statistically significant. The co-primary endpoints assessed the rate of change in cognitive abilities or episodic memory function, measured by the API ADAD composite cognitive total score and the Free and Cued Selective Reminding Test (FCSRT) Cueing Index, respectively. Crenezumab was generally well tolerated during the study and no new safety issues were identified. Further analyses of data are ongoing. Initial data will be presented at the Alzheimer's Association International Conference (AAIC) on August 2, 2022. The trial enrolled 252 people who are members of the world’s largest extended family with ADAD in Colombia. Two-thirds of participants carried the Presenilin 1 E280A mutation which typically causes cognitive impairment due to Alzheimer’s disease around age 44. Participants were randomised to receive crenezumab or placebo over five to eight years. During the trial, the dose of crenezumab was increased as knowledge about potential treatment approaches for Alzheimer’s disease evolved. The study, which was supported by National Institute on Aging, generous philanthropic contributions to Banner Alzheimer’s Foundation, and Roche, has generated a wealth of data that will advance the early detection, tracking and study of Alzheimer’s disease and inform the design of future Alzheimer’s prevention trials. Crenezumab is an investigational treatment discovered by AC Immune SA and designed to neutralise a pathological species of the beta-amyloid protein called oligomers. It is developed by Genentech, a member of the Roche Group, under a license and collaboration agreement established in 2006. The Alzheimer’s Prevention Initiative (API) is an international collaborative formed in 2009 to launch a new era of Alzheimer’s prevention research. Led by the Banner Alzheimer’s Institute, the API conducts prevention trials in cognitively healthy people at increased risk for Alzheimer’s disease. API continues to establish brain imaging, fluid biomarker and cognitive endpoints needed to rapidly test promising prevention therapies. It also leads participant recruitment registries to accelerate enrollment into Alzheimer’s-focused studies. API is intended to provide the scientific means, accelerated approval pathway and enrollment resources needed to evaluate the range of promising Alzheimer’s prevention therapies and find ones that work without losing another generation. First proposed by investigators from BAI, the API ADAD trial (NCT01998841) was a prospective, randomised, double-blind, placebo-controlled, parallel-group label enabling Phase II study of the efficacy of crenezumab versus placebo in cognitively unimpaired individuals who have no clinical symptoms of Alzheimer’s disease and carry the PSEN1 E280A autosomal dominant mutation. Participants who are mutation carriers were randomised in a 1:1 ratio to receive either crenezumab or placebo for at least 260 weeks. Crenezumab was initially administered subcutaneously 300 mg every two weeks. Dosing was amended in 2015 to 720 mg subcutaneously every two weeks and in 2019 the option to increase the dose to 60 mg/kg, delivered intravenously every four weeks, was offered to participants. A cohort of participants (non-mutation carriers) were also enrolled and dosed solely on placebo. The trial, which was supported by National Institute on Aging's (NIA) generous philanthropic contributions to Banner Alzheimer’s Foundation and Roche, was the first NIH-supported prevention trial of an experimental prevention therapy in cognitively unimpaired persons at known risk for the disease.

Neutral

AC Immune SA Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 08:00 AM

2022-05-31 11:30:00

AC Immune SA Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 08:00 AM. Venue: Marriott Marquis, New York City, New York, United States. Speakers: Andrea Pfeifer, Co-Founder, CEO & Director.

Neutral

AC Immune SA, Annual General Meeting, Jun 24, 2022

2022-05-25 20:30:00

AC Immune SA, Annual General Meeting, Jun 24, 2022, at 14:30 Central European Standard Time. Agenda: To consider 2021 IFRS Consolidated Financial Statements, 2021 Statutory Annual Report and 2021 Compensation Report ;to consider appropriation of loss; to consider Discharge of the Board of Directors and of the Executive Committee; to consider compensation for the Members of the Board of Directors and the Executive Committee; to consider re-election of directors and board members; to consider changes to the Articles of Association; and to consider other matters.

Neutral

AC Immune SA has closed its Shelf Registration dated August 24, 2018 in the amount of $57.7312 million.

2022-05-19 00:00:00

AC Immune SA has closed its Shelf Registration dated August 24, 2018 in the amount of $57.7312 million. Security Name: Common Shares Securities Offered: 18,041,000

Positive

AC Immune SA's Anti-Abeta Vaccine Results from Phase 1b Study in Down Syndrome Published in JAMA Neurology

2022-05-09 15:00:00

AC Immune SA announced the publication in JAMA Neurology1 of data showing that AC Immune’s ACI-24 anti-Abeta vaccine was found to be safe and elicited immune response in a Phase 1b clinical trial in adults with DS. This is the first anti-Abeta vaccine study conducted with people living with DS. The landmark study was led by principal investigator Michael Rafii, MD, Ph.D., Professor of Neurology at Keck School of Medicine of the University of Southern California and Medical Director of the Alzheimer’s Therapeutic Research Institute (ATRI). The phase 1b multicenter, placebo-controlled clinical trial was a collaboration between AC Immune, the Alzheimer’s Disease Cooperative Study (ADCS), and clinical investigators at Massachusetts General Hospital, Barrow Neurological Institute and University of California San Diego, with financial support from the National Institute on Aging, part of the National Institutes of Health, and the LuMind IDSC Down Syndrome Foundation. As presented in the JAMA Neurology article, the ACI-24 vaccine demonstrated immunogenicity along with pharmacodynamic and target engagement evidence as measured by a greater increase in plasma Abeta40 and Abeta42 in treated groups compared to placebo. Importantly, anti-Abeta antibody titers were not associated with any adverse findings. An optimized formulation of ACI-24 has demonstrated strong immunogenicity, inducing a polyclonal response in non-human primates against Abeta and, importantly, high titers of antibodies targeting pyroGlutamate-Abeta (as published in Brain Communications). This neurotoxic species of Abeta found in amyloid plaques is a key driver of disease progression2. Additional data on the optimized formulation were presented at the AD/PD™ 2022, Alzheimer's & Parkinson's Diseases Conference held on March 15-20.

Neutral

AC Immune SA Presents at B. Riley Securities's 2022 Virtual Neurology & Ophthalmology Conference, Apr-28-2022 11:30 AM

2022-04-27 11:55:00

AC Immune SA Presents at B. Riley Securities's 2022 Virtual Neurology & Ophthalmology Conference, Apr-28-2022 11:30 AM. Speakers: Andrea Pfeifer, Co-Founder, CEO & Director.

Negative

AC Immune SA Announces Executive Changes

2022-04-08 11:36:00

AC Immune SA announced senior management changes. Howard Donovan will join the Company as Chief HR Officer and be appointed to the Executive Committee. Christopher Roberts, Associate Vice President, Finance, was promoted to Vice President, Finance. Julian Snow, Associate Vice President, Financial Reporting, was promoted to Vice President, U.S. Finance & Corporate Development. Julian Snow, Associate Vice President, Financial Reporting, was promoted to Vice President, U.S. Finance & Corporate Development. Howard Donovan is an internationally experienced, commercially focused leader who has competencies in all aspects of employee services, well-being, benefit design, international mobility, talent management, operations and HR business partnering. Howard previously worked as the inhouse Global Head of Reward for Puma Energy and prior to that he held senior HR leadership roles with a strong reward focus with multinational companies, including SGS Group and Xerox Corporation.

Negative

AC Immune SA Announces Senior Management Changes

2022-04-08 11:36:00

AC Immune SA announced senior management changes. Joerg Hornstein, Chief Financial Officer, will leave in the second half to pursue a new opportunity. Christopher Roberts appointed as interim CFO.

Neutral

B. Riley Securities, Inc., B. Riley Securities's 2022 Virtual Neurology & Ophthalmology Conference, Apr 27, 2022 through Apr 28, 2022

2022-03-31 16:27:00

B. Riley Securities, Inc., B. Riley Securities's 2022 Virtual Neurology & Ophthalmology Conference, Apr 27, 2022 through Apr 28, 2022.

Neutral

AC Immune SA - Special Call

2022-03-29 00:00:00

Key Opinion Leader Webinar

Neutral

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022

2022-02-14 21:00:00

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New York, United States.

Positive

AC Immune ACI-24 Data in Brain Communications Show Abeta Vaccine-Candidate Induces Immunity Against pyroGlu-Abeta, Key Driver of Alzheimer’s Disease

2022-02-04 12:30:00

AC Immune SA announced that preclinical data on the optimized formulation of its wholly-owned amyloid-beta (Abeta) vaccine program, ACI-24, were published in the peer reviewed journal Brain Communications. Based on these and other preclinical data, as well as the results of three clinical trials with ACI-24, AC Immune plans to advance clinical development of the optimized formulation to the next stage for both Alzheimer’s disease (AD) and Down syndrome (DS) related AD in 2022. Pyroglutamate Abeta (pyroGlu-Abeta) peptides, truncated forms of the Abeta protein, are highly neurotoxic Abeta species, which are observed only in brain amyloid plaques and believed to be key drivers of AD1. PyroGlu-Abeta peptides’ altered biochemical properties make them more prone to aggregation compared to full-length Abeta and they are a major component of neurotoxic amyloid plaques. A recently published Phase 2 clinical trial showed that a monoclonal antibody targeting pyroGlu-Abeta epitope demonstrated slowing of cognitive and functional decline in early Alzheimer disease patients. Data published in the Brain Communications paper show the optimized ACI-24 formulation induced a broad polyclonal anti-Abeta response, including high titers of antibodies targeting pyroGlu-Abeta variants, and was well tolerated in non-human primates and mice. Specifically, in the study, conducted in mice and non-human primates, optimized ACI-24 generated a strong immune response against both the full length Abeta (Abeta1-42) and pyroGlu-Abeta. Importantly, the anti-pyroGlu-Abeta immune response observed in this newly published study was substantially stronger in animals vaccinated with the optimized ACI-24 vaccine formulation compared to those vaccinated with earlier Abeta vaccines from other companies that have been clinically tested (AN1792 and ACC-001) in this study.

Neutral

AC Immune SA Presents at Inflammasome Therapeutics Summit 2021, Nov-17-2021 12:00 PM

2021-11-12 18:04:00

AC Immune SA Presents at Inflammasome Therapeutics Summit 2021, Nov-17-2021 12:00 PM. Speakers: Marie Kosco-Vilbois, Chief Scientific Officer.

Positive

AC Immune SA Presents New Interim Phase 1b/2a Data on ACI-35.030

2021-11-12 13:21:00

AC Immune SA presented new interim Phase 1b/2a data on ACI-35.030, a first-in-class anti-phosphorylated-Tau (pTau) vaccine candidate being developed in partnership with Janssen Pharmaceuticals Inc., at the 14th Clinical Trials on Alzheimer's Disease (CTAD) conference, which is being held in Boston, Massachusetts from November 9-12, 2021. ACI-35.030 is the first AD vaccine candidate designed to generate antibodies targeting pathological pTau in the brain. At CTAD, AC Immune’s Chief Medical Officer Johannes Streffer gave an on-demand oral presentation featuring data from an ongoing, placebo-controlled Phase 1b/2a trial evaluating ACI-35.030 in participants with early Alzheimer’s disease (AD). Results from the trial show that ACI-35.030 treatment led to the strong induction of antibodies specific for pathological forms of Tau such as pTau and its aggregated form, enriched paired helical filaments (ePHF). Additional key findings from the CTAD presentation include: Anti-pTau IgG titers increased by two orders of magnitude from baseline already two weeks after the first injection of the mid-dose of ACI-35.030. Anti-ePHF IgG titers increased by one order of magnitude from baseline as early as two weeks after the second injection at week 8 of the mid-dose of ACI-35.030. The anti-ePHF IgG response was boosted following additional doses at weeks 8 and 24. The ACI-35.030-induced immune response was lasting over an initial period of 26-weeks and showed class-switching from IgM to IgG. Interim safety data further support ACI-35.030’s favorable safety and tolerability profile, with no clinically relevant safety concerns observed to date. As previously announced, the ongoing Phase 1b/2a study has been expanded to include a total of 24 AD participants in the mid-dose sub-cohort. This expansion was designed to support the advancement of ACI-35.030 into late-stage development.

Positive

AC Immune Announces Late-Breaker Presentation by Genentech at CTAD on Phase 2 Lauriet Study of Semorinemab in Mild-to-Moderate Alzheimer’s Disease

2021-11-10 16:20:00

AC Immune SA announced that Genentech, a member of the Roche Group, presented the full topline data from Lauriet, a placebo-controlled Phase 2 study evaluating the safety and efficacy of the investigational anti-Tau monoclonal antibody, semorinemab, in mild-to-moderate Alzheimer’s disease (AD) during a late-breaking session at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) Conference. Previously announced topline results showed that the trial met one of its two co-primary endpoints by demonstrating a statistically significant 43.6% reduction in the rate of cognitive decline with semorinemab compared to placebo (p1 dose of study drug and had at least one post-baseline ADAS-Cog11 assessment. Data from this population show a 42.2% reduction in the rate of cognitive decline with semorinemab compared to placebo (p=0.0008), as measured by ADAS-Cog11. This treatment effect was observed consistently in prespecified subgroups based on disease severity, baseline Tau load, and ApoE carrier status. ADAS-Cog11 domain analyses show that semorinemab’s treatment effect was driven predominantly by the memory domain, which is a core feature of AD. As previously announced, no significant treatment effect was observed on the trial’s other co-primary endpoint or the secondary endpoints.

Neutral

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022

2021-10-29 14:57:00

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022. Venue: New York, New York, United States.

Negative

AC Immune SA Announces Board Changes

2021-10-29 10:00:00

AC Immune SA announced that the Company held an extraordinary general meeting (EGM) and elected Monica Shaw, M.D., and Prof. Monika Bütler, Dr. oec., to its Board of Directors. Dr. Shaw and Prof. Bütler replace Mr. Martin Velasco and Peter Bollmann, Ph.D., who stepped down from the Board following the EGM. Monica Shaw, M.D., is a pharmaceutical industry expert who has held senior leadership positions and was involved in advancing more than 15 therapeutic products from first-in-human studies through regulatory approvals and commercialization across multiple geographies. She also played key business development roles in company acquisition and integration and co-development partnerships. Through her work, Dr. Shaw gained extensive specialty experience in the fields of dermatology, immuno-inflammation, HIV, neurology, and oncology. Currently, Dr. Shaw is Executive Vice President Head Region Europe, Canada, Australia, for Leo Pharma. She has previously held broad leadership roles at other leading pharmaceutical companies, including as Vice President Commercial Head Asia Pacific region at GSK/ViiV Healthcare, and Medical Director and Chief Scientific Officer UK for Novartis, in addition to previous leadership positions at Norgine, Shire and Merck KGaA. Prof. Monika Bütler, Dr. oec., is a leading Swiss economist and former Vice President of the independent Swiss COVID-19 Science Taskforce. She is a member of the Board of Directors and the audit committees of both Schindler Holding AG and Huber & Suhner AG. Prof. Bütler is also a member of the Swiss National Bank’s Council, where she serves on the remuneration committee. Her international economic expertise is in public policy and managerial economics, including an advisory role to the World Bank and work in the U.S. and Europe. Prof. Bütler is a Vice President of the Foundation Board of the Gebert Rüf Foundation, a science and innovation foundation that supports entrepreneurial projects which are committed to achieving an impact.

Neutral

AC Immune SA Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-16-2021 through Nov-19-2021

2021-10-25 11:00:00

AC Immune SA Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-16-2021 through Nov-19-2021. Venue: London, United Kingdom. Presentation Date & Speakers: Nov-18-2021, Andrea Pfeifer, Co-Founder, CEO & Director. Nov-19-2021.

Positive

AC Immune SA (NasdaqGM:ACIU) completed the acquisition of Assets and Intellectual Property Related to Anti-Alpha-Synuclein Programs of AFFiRiS AG.

2021-10-13 00:00:00

AC Immune SA (NasdaqGM:ACIU) agreed to acquire Assets and Intellectual Property Related to Anti-Alpha-Synuclein Programs of AFFiRiS AG for $58.7 million on July 27, 2021. The all-stock acquisition is valued at $58.7 million and $5 million in cash for 7.1 million shares of AC Immune common stock based on a price of $8.26 per common share. The acquisition is subject to customary regulatory approval in Austria and expected to complete at the beginning of Q4 2021. Rolf Watter, Vera Naegeli, Lukas Roesler, Rebecca Schori, Michael Rohrer and Linus Zweifel of Bär & Karrer Ltd. acted as legal advisor to AC Immune SA. AC Immune SA (NasdaqGM:ACIU) completed the acquisition of Assets and Intellectual Property Related to Anti-Alpha-Synuclein Programs of AFFiRiS AG on October 13, 2021

Neutral

AC Immune SA, Special/Extraordinary Shareholders Meeting, Oct 29, 2021

2021-10-07 11:27:00

AC Immune SA, Special/Extraordinary Shareholders Meeting, Oct 29, 2021, at 11:00 Central European Standard Time.

Neutral

AC Immune SA Proposes Amendments of the Articles of Association

2021-10-07 11:27:00

AC Immune SA proposing to the Shareholders in its EGM held on October 29, 2021 to accept certain changes to the Company's Articles of Association on three topics: Extension and addition of Authorized Share Capital Increase of the Conditional Share Capital for Bonds and Similar Debt Instruments Increase of the Conditional Share Capital for Employee Benefit Plans.

Neutral

Hanson Wade Limited, Inflammasome Therapeutics Summit 2021, Nov 16, 2021 through Nov 18, 2021

2021-10-04 11:08:00

Hanson Wade Limited, Inflammasome Therapeutics Summit 2021, Nov 16, 2021 through Nov 18, 2021.

Neutral

AC Immune SA Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-10-2021

2021-09-02 11:00:00

AC Immune SA Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-10-2021 . Venue: New Windsor, United States.

Neutral

AC Immune SA Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-12-2021 through Sep-16-2021

2021-09-02 11:00:00

AC Immune SA Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-12-2021 through Sep-16-2021. Venue: Lotte New York Palace Hotel, New York City, New York, United States. Presentation Date & Speakers: Sep-13-2021, Andrea Pfeifer, Co-Founder, CEO & Director. Sep-15-2021, Andrea Pfeifer, Co-Founder, CEO & Director.

Neutral

AC Immune SA Presents at Citi’s 16th Annual BioPharma Virtual Conference, Sep-08-2021

2021-09-01 19:46:00

AC Immune SA Presents at Citi’s 16th Annual BioPharma Virtual Conference, Sep-08-2021 . Venue: New York, United States.

Positive

AC Immune SA Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer’s Disease

2021-08-31 11:30:00

AC Immune SA announced that Genentech, a member of the Roche Group, has informed the Company that Lauriet, a placebo-controlled Phase 2 study evaluating the safety and efficacy of the investigational anti-tau monoclonal antibody, semorinemab, in mild-to-moderate Alzheimer’s disease (AD), met one of its co-primary endpoints, ADAS-Cog11. The second co-primary endpoint, ADCS-ADL, was not met. Safety data showed that semorinemab is well tolerated with an acceptable safety profile and no unanticipated safety signals. Semorinemab demonstrated a statistically significant reduction in cognitive decline from baseline by 43.6% compared to placebo (p<0.0025) as measured by the Alzheimer’s Disease Assessment Scale, Cognitive Subscale, 11-item Version (ADAS-Cog11) at week 49 in people with mild-to-moderate AD (i.e., Mini-Mental State Examination (MMSE) 16-21). There was no effect on the other co-primary endpoint of reducing the rate of functional decline from baseline as measured by the Alzheimer’s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) or secondary efficacy endpoints for the Mini-Mental State Examination (MMSE) or the Clinical Dementia Rating-Sum of Boxes (CDR-SB). The safety was consistent with previous clinical data reported. Genentech has reported that the open label portion of the study will continue as planned. Further analyses are ongoing, and top-line data will be submitted for presentation at the CTAD conference (Clinical Trials on Alzheimer's Disease conference) in November.

Neutral

AC Immune SA Presents at Alzheimer's Association International Conference, Jul-29-2021 10:00 AM

2021-07-29 11:30:00

AC Immune SA Presents at Alzheimer's Association International Conference, Jul-29-2021 10:00 AM. Venue: Denver, Colorado, United States.

Positive

AC Immune SA Presents Full Phase 1B Results on Anti-Abeta Vaccine and Discusses its Diagnostic for Parkinson’s Disease at AAIC 2021

2021-07-29 11:30:00

AC Immune SA announced that it outlined two presentations being delivered at the Alzheimer’s Association International Conference (AAIC) 2021, taking place both in Denver, USA and virtually from July 26, 2021 to July 30, 2021. The presentations highlight precision medicine approaches to enable the early detection and prevention of neurodegenerative diseases by targeting amyloid beta (Abeta) and alpha-synuclein (a-syn). The first virtual oral presentation includes the full results from phase 1b clinical trial evaluating the anti-Abeta vaccine ACI-24 in adults with DS. Previously announced topline data from the trial showed that ACI-24 generated evidence of immunogenicity along with a positive pharmacodynamic response and a favorable safety and tolerability profile. The phase 1b study results showed that ACI-24 was safe and well tolerated in adults with DS. No serious adverse events or evidence of central nervous system (CNS) inflammation, meningoencephalitis, or ARIA (amyloid-related imaging abnormalities), including ARIA-E (edema) and ARIA-H (hemorrhage), were reported. Data also showed that administration of ACI-24 resulted in encouraging immune responses that correlated with increases in plasma Abeta, which are indicative of target engagement. In addition, the company is also presenting a poster on ACI-12589, a first-in-class positron emission tomography (PET) imaging tracer targeting a-syn that is being developed as a first-in-class diagnostic for Parkinson’s disease (PD). Previously reported preclinical data confirm that the Morphomer®-derived candidate has a desirable brain-PET ligand pharmacokinetic profile in non-human primates. These and other prior data demonstrating ACI-12589’s signal specificity on tissue samples from patients with alpha-synucleinopathies, including PD, multiple system atrophy (MSA) and dementia with Lewy bodies (DLB) are being discussed in this poster presentation.

Positive

AC Immune SA - M&A Call

2021-07-27 11:30:00

To discuss on Strategic Acquisition of Parkinson’s Disease Vaccine Candidate and Equity Investment Led by Athos Service GmbH

Positive

AC Immune SA announced that it expects to receive $25 million in funding from First Capital Partner GmbH, ATHOS Service GmbH

2021-07-27 00:00:00

AC Immune SA entered into convertible note agreements to issue 2 unsecured subordinated convertible note at the price of $12.5 million per note for gross proceeds of $25 million on July 27, 2021. The transaction will include participation from new investors First Capital Partner GmbH and ATHOS Service GmbH and each will invest $12.5 million. The notes are convertible into common shares after the closing date of the asset purchase agreement at any time at the option of the investors or of company at a conversion price of $8.26. These options are effective from the signing date of the convertible note agreements until 10 calendar days prior to the repayment date. If the convertible notes are not converted during the conversion period, they shall be repaid on the repayment date, which is July 26, 2022. The convertible notes do not permit partial settlement and do not bear interest.

Positive

AC Immune SA (NasdaqGM:ACIU) agreed to acquire Assets and Intellectual Property Related to Anti-Alpha-Synuclein Programs of AFFiRiS AG for $58.7 million.

2021-07-27 00:00:00

AC Immune SA (NasdaqGM:ACIU) agreed to acquire Assets and Intellectual Property Related to Anti-Alpha-Synuclein Programs of AFFiRiS AG for $58.7 million on July 27, 2021. The all-stock acquisition is valued at $58.7 million and $5 million in cash for 7.1 million shares of AC Immune common stock based on a price of $8.26 per common share. The acquisition is subject to customary regulatory approval in Austria and expected to complete at the beginning of Q4 2021. Rolf Watter, Vera Naegeli, Lukas Roesler, Rebecca Schori, Michael Rohrer and Linus Zweifel of Bär & Karrer Ltd. acted as legal advisor to AC Immune SA.

Neutral

Alzheimer's Association, Alzheimer's Association International Conference, Jul 26, 2021 through Jul 30, 2021

2021-07-02 00:00:00

Alzheimer's Association, Alzheimer's Association International Conference, Jul 26, 2021 through Jul 30, 2021. Venue: Denver, Colorado, United States.

Fundamental Summary

Looking at AC Immune's financials of Q4 reflected unimpressive, mediocre results. This typically translates into the stock performing on par with market performance for the upcoming quarter. Therefore, they earned a total score of 68 out of 100 and a HOLD recommendation.

AC Immune reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported net loss was CHF 18.85 million compared to CHF 16.73 million a year ago. Basic loss per share from continuing operations was CHF 0.23 compared to CHF 0.23 a year ago.

Business Description

AC Immune, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer’s disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Sector Overview

AC Immune is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. AC Immune's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 261.4 28.5% 64
Liabilities 29.5 21.9% 84
Price to Book 1.5 -41.0% 75
Cash & Equivalents 82.2 -12.1% 53
Equity 232.0 29.4% 47
EBITDA -76.6 -5.4% 61
Total Revenues 0.9 0.0% 83
Parameter Value Change Score
Return on Equity -32.6 5.5% 65
Net Cashflow -78.7 5.2% 66
Capital Expenditure -2.6 3.1% 79
Asset Turnover 0.0 0.0% 63
Free Cashflow -0.9 5.6% 77

* All values are TTM

The below chart reflects AC Immune's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While AC Immune's peer average final assessment score stands on 61.0, AC Immune's score is 68.

  •  ACIU
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 0 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 1 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 2 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 3 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 4 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 5 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 6 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 7 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 8 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 9 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 10 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 11 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 12 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 13 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 14 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 15 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 16 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 17 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 18 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 19 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 20 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 22 1
Amgen Inc. 130.1B 69 78 81
Hold
77
77 23 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 24 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 26 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 27 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 28 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 30 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 31 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 32 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 33 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 34 1
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 35 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 36 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 37 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 38 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 39 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 40 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 41 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 42 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 43 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 44 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 46 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 47 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 48 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 50 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 52 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 53 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 54 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 55 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 56 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 57 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 58 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 59 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 60 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 61 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 62 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 63 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 65 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 66 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 68 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 69 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 70 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 71 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 72 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 73 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 74 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 75 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 76 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 77 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 78 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 79 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 80 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 81 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 82 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 83 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 84 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 85 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 87 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 88 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 89 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 90 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 91 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 92 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 93 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 94 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 95 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. AC Immune's stock is now priced above its 5-day and 50-day, but below its 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is strengthening. Historically, this is a positive setup in both the short and medium-term. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), AC Immune's stock indicates that it's likely oversold. Overall, these technical indicators don't clearly signal directional momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 68.

Neutral 68
Close Price 3.88
52W Low 2.35
52W High 8.34
5D MA 3.39
50D MA 3.28
200D MA 4.71
MACD 0.02
RSI 0.4
STOCH 100.0

Balance Sheet Analysis

Two main balance sheet metrics are driving the positive outlook for AC Immune's financial strength going forward. AC Immune has done an excellent job managing its liabilities. AC Immune's liabilities stood at 29.5 in the current filing, which represents a 21.9% change from the previous report. These numbers show that management has successfully encouraged growth while managing liabilities, especially relative to their peers. These results statistically lead to positive movement in stock prices, so we rated its liabilities movement component 84. Also, AC Immune's price to book ratio (P/B) was reported as 1.5 and represents -41.0% change from the previous report. Their industry-leading book value factors momentum reinforces an expectation for future positive momentum for their stock price going forward. The company's book value factors component, therefore, received a grade of 75. However, one discouraging result, Equity, stood out. AC Immune management produced disappointing equity metrics this period, which stood at 232.0, representing a 29.4% change. This parameter often affects companies in the same industry and market capitalization by up to 7.7%. This performance is significantly less impressive than its peers and competitors. Therefore, their equity movement component earned a score of 47. Therefore, it received a score of 68.

Parameter Value Change Score
Assets 261.4 28.5% 64
Liabilities 29.5 21.9% 84
Price to Book 1.5 -41.0% 75
Cash & Equivalents 82.2 -12.1% 53
Equity 232.0 29.4% 47
* All values are TTM

The below chart describes AC Immune's performance as reflected on its balance sheet with respect to its peers. While AC Immune received a balance sheet score of 68, the average of its peers stands on 62.0.

  •  ACIU
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 0 1
CureVac N.V. 2.6B 49 64 75 52 52 57 1 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 2 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 3 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 4 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 5 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 6 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 7 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 8 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 9 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 10 1
CareDx, Inc 1.2B 54 67 52 39 51 52 11 1
MannKind Corporation 957.2M 79 59 50 40 64 57 12 1
Merus N.V. 941.6M 59 68 50 83 81 70 13 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 14 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 15 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 16 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 17 1
Affimed N.V. 415.0M 56 66 63 56 47 54 18 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 19 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 20 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 22 1
Amgen Inc. 130.1B 72 68 86 53 62 69 23 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 24 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 26 1
BioNTech SE 34.0B 75 69 64 97 73 75 27 1
Seagen Inc. 32.9B 59 68 55 43 66 61 28 1
Biogen Inc. 29.7B 57 72 92 50 76 76 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 30 1
Incyte Corporation 16.8B 71 72 95 82 79 83 31 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 32 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 33 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 34 1
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 35 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 36 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 37 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 38 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 39 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 40 1
Alkermes plc 5.0B 63 66 46 54 71 62 41 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 42 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 43 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 44 1
Natera, Inc. 3.6B 73 65 43 95 42 54 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 46 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 47 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 48 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 50 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 52 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 53 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 54 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 55 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 56 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 57 1
Vericel Corporation 1.1B 51 65 56 53 61 57 58 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 59 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 60 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 61 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 62 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 63 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 65 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 66 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 68 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 69 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 70 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 71 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 72 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 73 1
Geron Corporation 566.2M 69 72 37 59 62 60 74 1
Immatics N.V. 538.7M 56 70 84 95 73 76 75 1
Agenus Inc. 520.5M 73 62 37 55 60 54 76 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 77 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 78 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 79 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 80 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 81 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 82 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 83 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 84 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 85 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 87 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 88 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 89 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 90 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 91 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 92 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 93 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 94 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 95 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

Two metrics jump up as the most significant positive drivers of the income statement's strength in AC Immune's recent report: Revenue Efficiency and Return Factors. AC Immune's financials reveal an interesting trend for their revenue efficiency. This characteristic can affect companies in the same industry and market capitalization by up to 12.9%. Their impressive revenue efficiency is even more impressive relative to its peers and competitors in the current market. The company's revenue efficiency, therefore, received a grade of 83. Also, Return factors metrics and ratios were exceptional in this report. AC Immune reported a return on equity (ROE) ratio of -32.6, representing a change of 5.5% from the last report. The company appears headed in the right direction in terms of these return factors, exhibiting prudent capital expenditure growth compared to its peers. Therefore, its return factors component earned a score of 65. On the other hand, EBITDA, jumped out as looking problematic. AC Immune's EBIDTA now sits at -76.6 and represents -5.4% change from the last reporting period. This metric might have a 23.8 percent impact on companies in the same industry and with the same market capitalization. The company's EBITDA metrics highlight a difficult overall financial situation, which may, unfortunately, continue moving forward unless management makes significant changes. Discouraging results like these statistically lead to negative pressure in stock prices, so we rated their EBITDA a grade of 61. Consequently, their income statement earned a rank of 70.

Parameter Value Change Score
EBITDA -76.6 -5.4% 61
Total Revenues 0.9 0.0% 83
Return on Equity -32.6 5.5% 65
* All values are TTM

The below chart describes AC Immune's performance as reflected on its income statement with respect to its peers. While AC Immune received a income statement score of 70 , the average of its peers stands on 65.0.

  •  ACIU
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 0 1
CureVac N.V. 2.6B 45 83 71 74 1 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 2 1
Abgenix Inc. 2.1B 47 47 47 47 3 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 4 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 5 1
Xencor, Inc. 1.6B 42 94 52 79 6 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 7 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 8 1
Veracyte, Inc. 1.4B 45 63 57 55 9 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 10 1
CareDx, Inc 1.2B 61 44 82 50 11 1
MannKind Corporation 957.2M 95 48 56 61 12 1
Merus N.V. 941.6M 48 60 59 54 13 1
Amarin Corporation plc 734.5M 95 44 82 63 14 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 15 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 16 1
Radius Health, Inc. 499.8M 94 71 68 82 17 1
Affimed N.V. 415.0M 95 49 75 66 18 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 19 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 20 1
Chimerix, Inc. 178.4M 99 50 62 65 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 22 1
Amgen Inc. 130.1B 74 75 64 78 23 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 24 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 26 1
BioNTech SE 34.0B 41 89 75 79 27 1
Seagen Inc. 32.9B 54 65 70 62 28 1
Biogen Inc. 29.7B 90 57 73 70 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 30 1
Incyte Corporation 16.8B 59 77 60 73 31 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 32 1
United Therapeutics Corporation 10.6B 57 91 54 82 33 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 34 1
Exact Sciences Corporation 7.2B 57 67 54 62 35 1
Exelixis, Inc. 6.7B 54 91 54 81 36 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 37 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 38 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 39 1
Ascendis Pharma A/S 5.2B 38 68 46 54 40 1
Alkermes plc 5.0B 69 55 81 62 41 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 42 1
Novavax, Inc. 4.0B 41 89 54 75 43 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 44 1
Natera, Inc. 3.6B 52 51 78 52 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 46 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 47 1
Insmed Incorporated 2.4B 51 58 73 57 48 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 50 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 52 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 53 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 54 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 55 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 56 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 57 1
Vericel Corporation 1.1B 76 44 82 56 58 1
IVERIC bio, Inc. 1.1B 84 58 79 70 59 1
FibroGen, Inc. 1.0B 48 74 63 67 60 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 61 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 62 1
ImmunoGen, Inc. 946.1M 40 73 71 64 63 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 65 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 66 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 68 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 69 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 70 1
CTI BioPharma Corp. 603.6M 84 50 62 59 71 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 72 1
AnaptysBio, Inc. 586.3M 97 50 77 68 73 1
Geron Corporation 566.2M 89 67 73 78 74 1
Immatics N.V. 538.7M 37 93 53 77 75 1
Agenus Inc. 520.5M 57 83 45 74 76 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 77 1
Vaxart, Inc. 440.0M 99 51 72 68 78 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 79 1
MiMedx Group, Inc. 391.5M 87 43 83 59 80 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 81 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 82 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 83 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 84 1
Zymeworks Inc. 324.7M 58 53 77 56 85 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 87 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 88 1
Silence Therapeutics plc 313.4M 83 64 69 72 89 1
Precigen, Inc. 299.1M 57 87 59 79 90 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 91 1
bluebird bio, Inc. 288.7M 99 91 61 96 92 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 93 1
MacroGenics, Inc. 184.6M 95 56 74 71 94 1
DermTech, Inc. 165.3M 49 48 78 52 95 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

Two metrics jump up as the most significant positive drivers of the cash flow's strength in AC Immune's recent report: Capex and Free Cash flow. AC Immune's management did a great job this period managing its capital expenditure (CapEx). In terms of the raw numbers, CapEx was reported as -2.6, which represents a 3.1% change from the last period. The company appears to be headed in the right direction regarding resource allocation, exhibiting prudent capital expenditure growth compared to its peers. The company's CapEx movement, therefore, received a grade of 79. Also, AC Immune's published free cash flow numbers were substantial and reflected management's focus on a healthy change strategy. AC Immune recorded free cash flow of -0.9, which represents a 5.6% change from the previous report. This parameter coud affect companies in the same industry and market capitalization by up to 2.8%. The company's free cash flow metrics are especially strong compared to its peers. Management seems to balance cash flow management, asset growth, and resource allocations in general. The company's free cash flow movement, therefore, received a grade of 77. That said, one metric, Asset Turnover, stood out as particularly concerning. AC Immune's asset turnover numbers were discouraging, reflecting significant concerns related to management's ability to leverage assets to generate sales effectively and efficiently. AC Immune recorded asset turnover of 0.0, which represents a 0.0% change from the previous report. Companies in the same sector and market capitalization will usually be affected by up to 3.2 percent by this parameter. The company's asset turnover metrics seem especially problematic relative to their peers. Correspondingly, their asset turnover movement received a grade of 63. Because its management is doing an excellent job managing these critical metrics, the cash flow was given a score of 68.

Parameter Value Change Score
Net Cashflow -78.7 5.2% 66
Capital Expenditure -2.6 3.1% 79
Asset Turnover 0.0 0.0% 63
Free Cashflow -0.9 5.6% 77
* All values are TTM

The below chart describes AC Immune's performance as reflected on its cash flow with respect to its peers. While AC Immune received a cash flow score of 68, the average of its peers stands on 64.0.

  •  ACIU
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 0 1
CureVac N.V. 2.6B 87 80 90 70 90 1 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 2 1
Abgenix Inc. 2.1B 66 53 45 59 58 3 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 4 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 5 1
Xencor, Inc. 1.6B 96 95 70 95 98 6 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 7 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 8 1
Veracyte, Inc. 1.4B 90 95 46 46 82 9 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 10 1
CareDx, Inc 1.2B 98 84 40 50 86 11 1
MannKind Corporation 957.2M 77 56 43 37 66 12 1
Merus N.V. 941.6M 70 71 74 53 71 13 1
Amarin Corporation plc 734.5M 52 40 74 55 55 14 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 15 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 16 1
Radius Health, Inc. 499.8M 64 40 37 56 57 17 1
Affimed N.V. 415.0M 72 57 95 43 74 18 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 19 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 20 1
Chimerix, Inc. 178.4M 80 84 95 47 83 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 22 1
Amgen Inc. 130.1B 80 74 67 74 81 23 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 24 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 26 1
BioNTech SE 34.0B 73 97 50 52 72 27 1
Seagen Inc. 32.9B 53 53 50 87 58 28 1
Biogen Inc. 29.7B 58 54 90 73 66 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 30 1
Incyte Corporation 16.8B 78 79 92 74 84 31 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 32 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 33 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 34 1
Exact Sciences Corporation 7.2B 53 45 80 46 56 35 1
Exelixis, Inc. 6.7B 79 90 89 83 87 36 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 37 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 38 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 39 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 40 1
Alkermes plc 5.0B 89 95 76 80 92 41 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 42 1
Novavax, Inc. 4.0B 62 38 63 54 60 43 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 44 1
Natera, Inc. 3.6B 52 54 56 84 58 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 46 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 47 1
Insmed Incorporated 2.4B 79 80 61 89 82 48 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 50 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 52 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 53 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 54 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 55 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 56 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 57 1
Vericel Corporation 1.1B 64 46 59 73 65 58 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 59 1
FibroGen, Inc. 1.0B 86 74 48 87 84 60 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 61 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 62 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 63 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 65 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 66 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 68 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 69 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 70 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 71 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 72 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 73 1
Geron Corporation 566.2M 78 68 49 81 77 74 1
Immatics N.V. 538.7M 82 95 56 99 86 75 1
Agenus Inc. 520.5M 57 43 52 77 58 76 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 77 1
Vaxart, Inc. 440.0M 72 56 53 38 65 78 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 79 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 80 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 81 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 82 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 83 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 84 1
Zymeworks Inc. 324.7M 52 65 45 83 57 85 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 87 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 88 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 89 1
Precigen, Inc. 299.1M 82 75 37 85 74 90 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 91 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 92 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 93 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 94 1
DermTech, Inc. 165.3M 60 51 45 86 58 95 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.